Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SCCHN Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Nivolumab, Ipilimumab, Cetuximab/Erbitux, Cisplatin/Platinol, Carboplatin/Paraplatin, Fluorouracil/Adrucil
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignancies
Interventions
INCA32459-101
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Intensity Modulated Radiation Therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced May 22, 2026, 4:11 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Lirilumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced May 22, 2026, 4:11 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Cancer
Interventions
Cisplatin, XRT
Drug · Radiation
Lead sponsor
Susanne Arnold
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions
PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced May 22, 2026, 4:11 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Larynx, Lip, Oral Cancer, Digestive Organs--Diseases
Interventions
Durvalumab, Intensity Modulated Radiotherapy Treatments
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced May 22, 2026, 4:11 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years to 99 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced May 22, 2026, 4:11 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma
Interventions
Ganetespib, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
19 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Setanaxib, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Calliditas Therapeutics Suisse SA
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Miami Beach, Florida • City of Saint Peters, Missouri • Creve Coeur, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced May 22, 2026, 4:11 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, stereotactic body radiation therapy
Biological · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced May 22, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
AT-101, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced May 22, 2026, 4:11 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced May 22, 2026, 4:11 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
ZD6474, Docetaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Maywood, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced May 22, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Capecitabine, Premedication
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Newark, Delaware • Chicago, Illinois • Elkhart, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced May 22, 2026, 4:11 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
Interventions
AFM24, SNK01
Drug · Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Cetuximab, Cisplatin, Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
95
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Laryngeal Cancer
Interventions
pembrolizumab (MK-3475), Cisplatin, Radiation
Drug · Radiation
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
4
States / cities
La Jolla, California • Bismarck, North Dakota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced May 22, 2026, 4:11 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PF-08046876
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 22, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Nivolumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
28
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced May 22, 2026, 4:11 AM EDT